Blackpeak Capital is pleased to present the June 2021 quarter update for the ANZ technology market – click on the link below:
For more information contact:
+61 416 335 455
Blackpeak is pleased to announce that it acted as Financial Advisor to Lumos Diagnostics (Lumos) on its IPO on the ASX. Lumos is a fully integrated developer and manufacturer of rapid, point-of-care (POC) diagnostic solutions. Lumos develops and manufactures proprietary and in-licensed POC diagnostic tests for commercial sale through distributors under its Products division, and develops and manufactures POC diagnostic tests on behalf of clients under its Commercial Services division. Lumos’ flagship proprietary product is FebriDx®, a point-of-care diagnostic test able to rapidly identify microbial infections in patients with acute respiratory infection symptoms and, if positive, determine if that infection is caused by a virus or bacteria.
Blackpeak is pleased to announce that it acted as financial adviser to Elevio on its sale to Dixa. Elevio (https://elev.io/) has an intelligent knowledge-centered platform that enables teams to deliver contextual knowledge to customers, support agents and internal teams. Dixa (https://www.dixa.com/) has a customer service software platform that enables brands to serve customers across multiple channels from a single screen including social media, chat, voice and messaging apps, enabling an outstanding experience for both customers and agents.
Announcements from Elevio and Dixa are below:
Below is a link to an AFR article on the deal.